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ABSTRACT 
 
Christina Elizabeth Story: Comparing Aerobic Exercise Intensity Determination In Acute 
Leukemia Patients 
(Under the direction of Claudio L. Battaglini) 
 
PURPOSE: To compare different heart rate (HR) methods commonly used to determine aerobic 
exercise intensity in acute leukemia patients (ALP). METHODS: 14 ALP completed a VO2peak 
test on a cycle ergometer with indirect calorimetry within 96 hours of admission at NC Cancer 
Hospital.  The % of 220-age equation and HR reserve methods were compared to HR at 
%VO2peak at 3 different exercise intensities; low (40%), moderate (60%) and high (75%). One-
Way ANOVAs were used to compare different methods at different intensities. RESULTS: No 
significant differences were observed between 220-age and HR at %VO2peak at moderate (100±8 
and 113±24bpm, p=.122) and high intensity (125±10 and 123±25bpm, p=.994). At low intensity, 
all methods were significantly different. CONCLUSION: In ALP, neither % of 220-age or HR 
reserve should be used to prescribe aerobic exercise intensity, however, at moderate and high 
intensities, the 220-age equation produced similar values to HR derived from %VO2peak. 
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CHAPTER ONE: INTRODUCTION 
 
Background 
 Hematological cancers will make up a relatively small portion of new cancer 
diagnoses in the year 2015 with estimated total occurrences of 162,020 out of 1,658,320 
new diagnoses of all cancers [American Cancer Society (ACS), 2015], and were expected 
to account for approximately 9.4% of cancer deaths overall in 2014 [Leukemia & 
Lymphoma Society (LLS), 2014].  Leukemia is the second-most common type of 
hematological cancer to occur with 54,270 new cases predicted this year (ACS, 2015). 
Out of all new leukemia diagnoses this year, Acute Myelogenous Leukemia (AML) will 
account for approximately 20,830 of those and over 10,000 deaths will be attributed to 
AML in 2015 (ACS, 2015).  Acute Lymphocytic Leukemia (ALL) will account for 
approximately 6,250 new diagnoses this year and over 1,400 deaths will be attributed to 
ALL (ACS, 2015).  The most common first treatment, induction chemotherapy, is 
successful in approximately 65% of AML patients and 80% of ALL patients, but the 
overall recovery and 5-year survival rate is significantly lower at less than 30% for AML 
patients and 40% for ALL patients (ACS, 2015).   
 The treatment plan for acute leukemia patients typically begins with induction 
chemotherapy for seven consecutive days, followed by three to four weeks of recovery 
time in the hospital.  Two types of chemotherapy agents are used together with the goal 
of remission (which is defined as less than 5% of leukemia cancer cells in the bone 
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marrow) following induction therapy.  After the recovery time, the next phase of 
treatment is called consolidation treatment, which is used to kill any remaining leukemia 
cells.  This phase consists of three or more cycles of chemotherapy with a single agent 
that is given in the hospital for 5 days.  The induction phase of seven continuous days of 
chemotherapy is intense for patients.  The systemic physical assault of the body with 
these chemotherapy agents affects the majority of the body’s physiological systems.  
Common side effects include nausea, diarrhea, fatigue, anemia, neutropenic fever and 
myelosuppression (Battaglini et al., 2011; Bryant et al., 2015).  Adult acute leukemia is a 
rare diagnosis and treatment has fluctuating side-effects which are commonly observed in 
the majority of patients, including significant loss of body mass and lean body mass, 
reduced physical functional capacity, severe pain, and depressive symptoms and anxiety.  
All are major contributors to significant reduction in overall quality of life in this patient 
population (Battaglini et al., 2009; Alibhai et al., 2012; Bryant, et al., 2015).   
Among treatment options such as chemotherapy and radiation in solid tumor 
cancers, exercise as an adjunct therapy has been shown to improve or decrease the 
decline of the outcomes (Schwitz, 2010).  In the case of hematological cancers, there is 
little published research examining the potential benefits of exercise training, however 
the results of these initial trials have presented relatively successful outcomes in the 
alleviation of treatment-related symptoms in this cancer population.  There is limited 
research yet to determine the most effective exercise prescription paradigm (i.e. mode, 
duration, intensity, frequency and timing within treatment) to maximize the potential 
exercise training benefits in patients with hematological cancers. Therefore it is 
paramount that additional studies are conducted to allow for the development of more 
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specific exercise plans for these patients with hematological malignancies (Battaglini et 
al., 2011).   
Leukemia affects the ability of the body to produce red blood cells (RBC) that 
carry oxygen throughout the body to the tissues and organs. For instance, a decreased 
RBC count and therefore inadequate oxygenation may create problems with shortness of 
breath, increased heart rate, light-headedness; all factors influencing negatively the 
patients cardiopulmonary function thus reducing these patient’s ability to exercise 
(National Library of Health, PubMed, 2013). However, in a previous study in patients 
with hematological cancers getting ready to undergo bone marrow transplantation, 
cardiopulmonary function has shown to be a strong predictor of post-transplant treatment 
complications and survival time (Wood et al., 2013).  
  Cardiopulmonary exercise testing (CPET) is the gold standard method of 
cardiopulmonary evaluation. It is a method that measures cardiopulmonary function 
objectively and it is often used for the determination of training thresholds in different 
populations including cancer patients (Jones et al., 2008). However, not every clinic or 
hospital has the equipment and personnel infrastructure to conduct CPET tests for the 
assessment of cardiopulmonary function and to use the results of a CPET to prescribe 
exercise intensity to their cancer patients. Examining other methods for the determination 
of exercise intensity that may produce accurate results when compared to the results of a 
CPET in a population so vulnerable to infections as AML patients may help clinicians to 
be able to prescribe exercise to their patients with less hassle and in a larger scale.  
Therefore, it is important to examine how well other methods of exercise intensity 
determination compare to the gold standard CPET.  
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Statement of Purpose 
 The purpose of this study was to compare the heart rate values computed from 
heart rate reserve method and the 220-age equation to heart rates obtained from a 
cardiopulmonary maximal exercise test for the determination of aerobic exercise intensity 
in newly diagnosed acute leukemia patients undergoing induction treatment. 
Research Questions 
RQ1: Is there a significant difference between heart rates derived from the heart rate 
reserve method when compared with heart rate values obtained from percent of the 
VO2peak test at the intensities of 40%, 60% and 75%? 
 
RQ2: Is there a significant difference between heart rates derived from the 220-age 
equation when compared with heart rate values obtained from percent of the VO2peak test 
at the intensities of 40%, 60% and 75%? 
Hypotheses:  
H1: There will be an overestimation of exercise prescription intensity using the heart rate 
reserve method for the determination of aerobic exercise intensity at 40%, 60% and 75% 
when compared with heart rate values derived from the percent of VO2peak test at 40%, 
60% and 75%.    
 
H2: There will be an overestimation of exercise prescription intensity using the 220-age 
maximal heart rate equation for the determination of aerobic exercise intensity at 40%, 
60% and 75% when compared with heart rate values derived from the percent of VO2peak 
test at 40%, 60% and 75%.    
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Definition of Terms:  
Leukemia: A type of cancer that affects bone marrow and blood.  The disease develops 
when cells formed in the bone marrow grow out of control.  (LLS, 2014) 
Acute Myeloid Leukemia (AML): A specific type of leukemia that affects several types 
of cells, which are not yet fully formed in the bone marrow (myeloid cells).  AML’s 
progression is considered fast (acute) and thus requires immediate intensive treatment for 
best survival outcomes.  (LLS, 2014) 
Acute Lymphocytic Leukemia (ALL): Also called Acute Lymphoid Leukemia, it is a 
specific type of leukemia that affects the bone marrow and blood.  It is seen most often in 
children and adolescents, but over the past few decades an increasing number of adult 
cases have also been seen.  (LLS, 2014) 
Peak Oxygen Uptake (VO2peak): Maximum rate of oxygen consumption as measured 
during incremental aerobic exercise and reflects aerobic physical fitness level.  In this 
paper it will be referred to as a relative rate of milliliters of oxygen consumed per 
kilogram of body mass per minute (mL/(kg*min)).  (Wikipedia, 2014) 
Heart Rate (HR): The speed at which the heart beats, measured as the number of beats in 
a specific unit of time (usually beats per minute).  A normal heart rate is between 60 and 
100 beats per minute (bpm) at rest.  HR can change according to the body’s needs in 
terms of physical activity in order to absorb oxygen and carry it through the bloodstream.  
Some factors that can affect HR include stress, disease, sleep, drugs, illness, and exercise. 
(Wikipedia, 2014) 
Heart Rate Reserve (HRR) Equation: (220–age–RHR)* %intensity + RHR.  (Karvonen, 
1957) 
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220-age Equation: (220-age) * % intensity (Robergs, 2002 and Fox, 1971) 
Assumptions: 
1. All of the participants followed pre-testing guidelines.  
2. Participants answered honestly on all questions related to their history of cancer, 
lifestyle, health and medical issues.   
3. On the peak oxygen consumption test, all participants gave maximum effort.   
Limitations:  
1. Sample was limited to adult acute leukemia patients currently undergoing 
treatment at UNC hospitals.  Therefore, the outcomes of this study are unable to 
be generalized to other cancer types or other clinical populations.   
2. Previous exercise history may have confounded outcomes.  
3. Previous experience (or lack thereof) with exercise testing protocols may have 
influenced a patient’s peak performance.   
Delimitations:  
1. All participants were adults, age 21 years and above.  
2. All participants were recently diagnosed with acute leukemia and received 
treatment at UNC hospitals.  
3. All participants underwent CPET test within 96 hours of admission.   
4. All participants received the same type of treatment plan of 7+3 induction 
chemotherapy.   
Significance of the Study:  
The timely completion of acute leukemia treatment is a major factor in achieving 
remission and thus increasing the rate of survival.  However, the severity of side effects 
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can decrease treatment plan compliance.  The fluctuating side effects found in the 
leukemia population during treatment, including fatigue, can lead to decreased fitness 
capacity and difficulties performing the activities of daily living.  This decreased 
functional capacity can lead to further fatigue and reduced ability to tolerate and 
complete treatment as planned.  Over 90% of AML patients report fatigue as one of their 
most distressing symptoms (Alibhai et al., 2012).  Bryant et al (2015) proposes that 
greater reductions in cancer-related fatigue are found in patients using moderate to high 
intensity exercise interventions.  Battaglini’s study in 2009 suggests that the continual 
negative cycle of decreased functional capacity and fatigue can be broken and quality of 
life can be maintained during treatment using exercise intervention.  An exercise 
intervention during treatment may also reduce the length of hospital stays thus decreasing 
time to remission status.   
However, there is no standardization of exercise protocols and therefore mixed 
degrees of success have been achieved regarding the desired outcome variables.  The 
restrictions of using fatigued, immune-compromised acute leukemia patients, who are 
required to stay in their room for the duration of induction treatment, creates some 
difficulties as which may not be encountered during standard exercise protocols among 
cancer survivors and other clinical populations.  Such difficulties include access to 
exercise equipment, exercise test availability and suitability as well as the infection risk 
to the patients.  
At this time, the recommendations for exercise are generalized for the cancer 
population and are the same as the Physical Activity Guidelines for Americans, including 
the recommendation of 150 minutes of moderate intensity exercise per week (Schmitz et 
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al, 2010).  Heart rate is used in most exercise intervention research programs because of 
its practicality in both supervised and unsupervised settings.  It is a relatively easy and 
inexpensive way to monitor exercise intensity for either an administrator or the patient 
themselves.  This leads to the simple question of which HR prediction method is more 
accurate to prescribe intensity of exercise. 
Both the Heart Rate Reserve (HRR) method and the 220-age equation multiply a 
percentage of intensity by the predicted maximum to find a HR value equivalent to the 
chosen intensity level.  For these equations, HR is assumed to increase in a linear fashion 
as intensity of exercise increases, and will move toward the maximum predicted value of 
220-age beats per minute (bpm) (Robergs, 2002).  A possible way to validate the use of 
the heart rate reserve and 220-age HR values at particular intensities is to perform a 
cardiopulmonary maximal exercise test (CPET) with HR values taken at small, regular 
intervals throughout the test. From the CPET test, a HR value at a certain intensity can be 
computed and compared to the predicted HR values given by the equations at the same 
level of intensity.   
 Currently the Heart Rate Reserve (HRR) method and the 220-age equation are 
two of the most commonly used methods to calculate HR values for varying levels of 
aerobic exercise intensity in different populations.  Investigating several exercise 
intensities in this study will enable us to determine if either equation can be used to 
accurately to prescribe exercise in this sample of cancer patients.  This is significant, 
since the use of the heart rate reserve and 220-age equation is easy to use and could assist 
exercise physiologists in the training of their patients with greater accuracy and without 
performing a CPET. Improving our understanding of the use of HR values for prescribing 
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exercise in acute leukemia patients will allow for clinicians to make a more informed 
decision as to which methods more closely correlate to the HR value derived from a 
CPET, which is considered the gold standard method for derivation of exercise intensity. 
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CHAPTER TWO: LITERATURE REVIEW 
 
 
Overview 
 For the purpose of organization, this literature review will be divided into four 
sections. Facts and statistics on cancer and leukemia will be reviewed in the first section.  
Acute leukemia treatments and common side effects will be discussed in the second 
section.  Studies on exercise and leukemia will be described in the third section.  Lastly, 
section 4 reviews the prescription of aerobic exercise using heart rate.   
Section 1: Statistics on Cancer and Leukemia 
 In the year 2015, over 1.6 million new cancer diagnoses are predicted, with more 
than 500,000 deaths from all cancer types.  Over 50,000 of those new diagnoses this year 
will be new leukemia cases, and approximately 24,000 deaths will be attributed to 
leukemia as well (ACS, 2015).  Those deaths from leukemia will account for 4.9% of all 
cancer deaths this year.  Acute Myeloid Leukemia (AML) is the most common type of 
acute leukemia in adults and the second most common type of leukemia overall.  Over 
20,000 new diagnoses are predicted in 2015 with over 1,600 of those occurring in North 
Carolina alone.  In regards to Acute Lymphocytic Leukemia (ALL), over 6,000 new 
cases will be diagnosed in 2015 (ACS, 2015).   
 Leukemia is a cancer that affects the bone marrow and the blood.  Disease occurs 
when the cell growth rate in the bone marrow is exponentially increased and out of 
control (ACS, 2014).  The type of leukemia is classified by the rate of cell growth (acute 
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or fast-growing versus chronic or slower growth) as well as the type of cell affected.  In 
AML, the bone marrow is manufacturing abnormal immature cells of several types, 
excluding certain white blood cells (lymphocytes).  Once a marrow cell becomes 
leukemic, it multiplies into over 10 billion cells that do not function normally and may 
prevent the production of other cells (LLS, 2014).  Unlike solid tumor cancers, the 
specific sub-type of cell that it affects, not stage numbers I-IV classify acute leukemia.   
AML typically has a greater incidence rate as age increases, with an average age 
at diagnosis of 66 years.  Overall, the lifetime chance of diagnosis is 1 in 227 for men and 
1 in 278 for women.  60-70% of AML patients achieve remission after the first phase of 
treatment, but only 25% are truly cured and survive more than 3 years giving AML the 
lowest long-term survival rate among the 4 different types of leukemia (LLS, 2014).   
Section 2: Acute Leukemia Treatments and Common Side Effects 
 The most common and effective first-line treatment for acute leukemia diagnoses 
is intense chemotherapy in two distinct stages, induction therapy and consolidation 
therapy.  Induction chemotherapy, the first phase, involves an intensive treatment with 
multiple chemotherapy drugs given in concert.  An anti-tumor drug such as Antracycline 
and a drug from the anti-metabolite group such as Cytarabine are often given in a 
structure called 7+3 intensive treatment.  This means that for 7 consecutive days, the anti-
metabolite drug is dosed intravenously and for the first 3 of those days, the anti-tumor 
drug is also given.  The goal of this very intensive treatment is to get rid of the leukemic 
cells, which are called leukemic blasts (LLS, AML Education Booklet).   
Following the seven days of treatment, the patient will take 4 to 6 weeks to recover in the 
hospital as their immune system has been entirely wiped out by the chemotherapy 
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treatment.  If the first round of treatment does not lead to remission, then a second round 
of induction chemotherapy will be started as soon as is tolerable by the patient. If the 
treatment has been successful, less than 5% of the bone marrow cells will be leukemic 
and the patient will progress to the next stage of chemotherapy treatment.   
Consolidation chemotherapy is the next stage of treatment following the induction 
phase.  The goal of this additional chemotherapy is to remain in remission and kill the 
remaining cancerous cells to hopefully prevent a recurrence or relapse.  The length of 
stay and treatment plan varies but generally involves several single-drug treatments 
spread throughout the week with time spent alternately in the hospital and at home.  This 
stage of treatment may also be paired with stem cell transplantation in certain cases to 
replace patient’s bone marrow with healthy non-cancerous cells.  (LLS, AML Education 
Booklet) 
Side effects from chemotherapy vary in number and intensity across patients and 
treatment plans, but the most common ones in acute leukemia patients will be discussed 
here.  The most serious effect of the chemotherapy is the low blood counts that result 
from the cell destruction of both cancerous and healthy cells in the bone marrow and 
blood.  Red blood cells (RBC), white blood cells (WBC) and platelets will all be lowered 
by induction chemotherapy treatment.  Transfusions of RBC and platelets are sometimes 
given to raise blood levels during the induction phase.  The most dangerous effect of 
these low blood counts, especially WBC, will be the increased chance of infection.  
Infections can cause the patient to become septic in just a few hours due to their reduced 
immune system, so treatment with antibiotics must be started immediately to improve 
chances of recovery.  
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Other physical side effects of chemotherapy are similar to those seen in other 
cancers such as mouth ulcers, diarrhea, hair loss, rash, nausea and vomiting.  Increases in 
anxiety, depression and fatigue are also often observed, with fatigue being reported as 
distressing by over 90% of AML patients (Alibhai et al, 2012).   
Section 3: Exercise and Leukemia 
 Exercises as an adjunct therapy has been proven successful and efficacious in 
several other types of cancer in improving fatigue, quality of life and functionality 
(Schmitz, 2010), and exercise research with hematological cancer populations such as 
leukemia have also shown positive benefits.  However, the limited number of studies 
regarding exercise in the acute leukemia population implies that the most effective 
methods and plans of exercise prescription for this population may not have yet been 
found or studied.  The research studies that will be reviewed are Chang et al (2008), 
Battaglini et al (2009), Klepin et al (2011), and Alibhai et al (2012).   
 Chang et al (2008) was the first study in this population, and the only randomized 
controlled clinical trial.  This study measured the outcomes of fatigue, 12-minute walking 
distance, symptom distress and mood disturbance both at baseline and at the completion 
of the 3-week program.  The intervention group completed a walking exercise program 
consisting of 12 minutes of accompanied walking in the hospital hallway 5 days per week 
at an intensity of resting heart rate (RHR) plus 30 beats per minute (bpm) monitored via 
portable HR monitor.  The study found statistically significant improvement in the 12 
minute walking distance, as well as non-significant improvement in fatigue intensity, 
anxiety and depression (mood disturbance).   
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 Battaglini et al (2009) completed assessments of fatigue, depression, quality of 
life (QOL), body composition, cardiovascular (CV) endurance, and dynamic muscular 
endurance at baseline and at study completion (approximately 6 weeks from start of 
treatment).  Each patient was prescribed an individualized plan of exercise 3-4 times per 
week with at least 12 hours between sessions.  Each session was divided into 2 bouts 
(AM and PM) and lasted for no longer than 30 minutes each.  Each bout consisted of 3-5 
minutes (min) of light stretching, 5-10min of cycling or treadmill walking, 5-15min of 
resistance training, and 5-10min of core exercises.  Intensity for aerobic exercise was 
determined using heart rate reserve (HRR) of 40-50% and RPE on the CR10 modified 
Borg scale.  RPE was monitored and never exceeded 5 on the 1-10 scale.  This study 
found statistically significant improvements in CV endurance, fatigue and depression.   
 The study by Klepin et al in 2011 looked at the variables of lower-extremity 
physical functioning, grip strength dynamometry, health-related QOL, and additional 
measures such as depression and distress.  The exercise intervention in this study 
consisted of group sessions offered 3-4 times per week for 4 weeks and included 5-15min 
of walking, 15min of tailored stretching and resistance training with resistance bands, and 
finishing with an additional 5-15min of walking.  The prescribed intensity for the walking 
portion was “light” and participants reported an average RPE of 10.5 on the Borg scale of 
6-20.  Outcomes included a clinically significant improvement in the lower-extremity 
physical functioning test, as well as statistically significant improvement in health-related 
QOL and depression.   
 The most recently published study by Alibhai et al in 2012 studied the outcome 
measures of aerobic fitness (modified Bruce protocol, calculating VO2 peak using ACSM 
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walking equation), 6-minute walk test, grip strength via dynamometer, lower body 
function via chair stand test, QOL, fatigue, depression and anxiety.  Based on the results 
of the tests, each patient was approached with an individualized exercise prescription of 
4-5 sessions per week for 30-45min per session and a total of 4-6 weeks.  Each session 
included minimum of 10 (maximum of 40min) of aerobic training, 10min (up to 25min) 
of resistance training, and 5-10min of flexibility training.  The intensity for the aerobic 
training was light to moderate and monitored via RPE scale of 3-6 (0-10 scale).  Aerobic 
exercise progression was achieved by increasing duration first, then by increasing 
intensity.  Improvements were clinically significant for fatigue, statistically significant for 
6-minute walk test and anxiety, and non-significant improvements were seen in VO2 peak 
and chair stand test.   
 Overall, each of these four studies prescribed varied exercise intervention during 
induction chemotherapy treatments and all showed statistically or clinically significant 
improvements in at least one variable of study.  Those improvements were seen in both 
quality of life measures, including anxiety, depression, and fatigue, as well as physical 
functioning and fitness measures such as 6-minute walk test, lower extremity function 
and cardiovascular endurance.  The methods of exercise prescription were varied in their 
mode, intensity and duration thus more research is needed to determine the most effective 
method of prescribing exercise so one can optimize the benefits of exercise in this cancer 
population.  The findings of research conducted today on the use of exercise as an 
intervention used to alleviate treatment-related symptoms support the use of exercise in 
acute leukemia patients undergoing induction chemotherapy.  
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Section 4: Prescriptions of Aerobic Exercise using Heart Rate 
 Several studies have looked at the prescription of aerobic exercise intensity in 
other cancer populations such as breast cancer.  One such study is by Evans et al (2009), 
which looked at HR, RPE and blood lactate (BL) values of breast cancer survivors as 
compared to healthy controls after aerobic exercise bouts.  Participants were taken 
through a short 9-minute bout at each of three intensities (40%, 60% and 70% of 
calculated VO2 peak); all variables were measured at the end of each bout.  No statistical 
differences between the groups were found for HR or RPE at any intensity level.  The 
cancer group was significantly lower in BL values at 70% intensity, but not at 40% or 
60%.   
 A second study by Kirkham et al in 2013 compared 4 methods of prescribing 
exercise intensity within and between 3 groups (recent breast cancer treatment 
completion, breast cancer survivors, and healthy controls) at 60% intensity.  The four 
methods of intensity prescription include ACSM metabolic equation for treadmill 
walking, direct measured relationship between HR and VO2 (HRdirect), the Heart Rate 
Reserve (HRR) method, and the RPE method.  Each method’s calculation of 60% was 
compared to 60% of VO2 reserve (= VO2 peak – VO2 rest) for each participant.  The study 
concluded that different methods of prescription were more accurate for certain groups 
than others.  For breast cancer patients and survivors, HRR method and the ACSM 
metabolic equation were found to be most accurate.  The four methods varied in accuracy 
and did not all achieve equivalent intensity prescription within each group.   
 These studies both present interesting and relevant research in regards to the 
comparison of methods of the prescription of exercise intensity.  Kirkham et al in 
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particular shows the discrepancy between the methods, while also describing the most 
accurate for the clinical population in question.  Unfortunately, both of these studies use 
breast cancer patients who have already completed treatment and are categorically 
different in their type of cancer and stage of cancer treatment, which allows for no 
comparison to be made to acute leukemia patients proposed in this study.   
 The exercise research in AML patients above has focused on feasibility and light 
to moderate prescription of exercise based on RPE or HRR.  However, no analysis of the 
accuracy of these methods has been completed in this population as they undergo 
intensive chemotherapy treatment and such analysis is needed to ensure that the 
population is receiving the most accurate and beneficial exercise prescription possible.  
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CHAPTER THREE: METHODOLOGY 
 
 
Participants 
Acute Leukemia patients newly diagnosed with acute myelogenous or acute 
lymphocytic leukemia, ages 21 years or greater, admitted to begin induction 
chemotherapy with an expected hospital stay of 3-4 weeks, and enrolled to participate in 
the EQUAL (Exercise and Quality of Life in Leukemia/Lymphoma Patients) phase II 
trial, were included in this study. Patients were made aware of the EQUAL phase II study 
by their oncologists, and after approval by the oncologist to participate in the study, 
patients were contacted by a research team member where patients received further 
information regarding the study protocol.  After the patients agreed to participate in the 
study, patients were asked to sign an informed consent form approved by the Lineberger 
Comprehensive Cancer Center Protocol Review Committee (LCCC PRC) and the 
University of North Carolina Institutional Review Board (IRB). All initial study 
assessments were performed within 96 hours of hospital admission.  
The inclusion criteria to enroll in the EQUAL phase II trial included: being newly 
diagnosed with acute leukemia (AML or ALL) based on pathology report, physician 
approval, age of 21 years or older, ability to speak and understand English.  The 
exclusion criteria were based on the risks of any normal exercise program, and included:  
cardiovascular disease; acute or chronic respiratory disease; acute or chronic bone, 
muscle or joint abnormalities; altered mental state, dementia, or any other psychological 
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condition that would prevent understanding of informed consent; another active 
malignancy; active bleeding, acute thrombosis, ischemia, hemodynamic instability, or 
uncontrolled pain.  These criteria were determined by reviewing the patient’s medical 
history and permission of the patient’s physician.  
A medical history questionnaire was completed to determine the patient’s medical 
and cancer history including treatment, level of physical activity, age, race and gender.  
Prior to enrollment, all possible patient participants underwent a complete physical 
evaluation conducted by the physicians who were part of the research team. The patients 
underwent an EKG, as well as an echocardiogram (ECHO) or MUGA test (Multigated 
Acquisition Scan) for the assessment of cardiovascular function. The MUGA test, also 
called equilibrium radionuclide angiogram or blood pool scan, evaluates the pumping 
function of the ventricles (ejection fraction).  
Instrumentation 
 For this study, only the data collected during the initial cardiopulmonary test were 
used from the patients enrolled in the EQUAL phase II trial. All tests were performed on 
a cycle ergometer (Monark 874E, Goteborg, Sweden) at the NC Cancer Hospital, 
Hematology Oncology Unit.  To determine oxygen uptake, expired gases were measured 
via a portable metabolic gas analysis system (Cosmed Portable K4b2, Rome, Italy). 
Blood pressure (BP) was monitored via auscultation using a sphygmomanometer 
(American Diagnostics Corporation, Hauppage, NY) and a Littman Stethoscope (3M, St. 
Paul, MN).  Heart rate (HR) values were be collected using a Polar telemetry system 
(Polar Electro Inc., Lake Success, NY) every 10 seconds during the CPET test.  The Borg 
Rate of Perceived Exertion (RPE) Scale (6-20) was used to monitor rate of perceived 
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exertion (RPE) (ACSM, 2013) in the patient at the end of each stage of the CPET and at 
the end of the test.  
Research Design Overview  
 This study was a retrospective study using data collected from the EQUAL phase 
II trial (IRB # 13-1082), a randomized clinical pilot trial that is being conducted by Dr. 
Ashley Leak Bryant and Dr. Claudio L. Battaglini.  The study was a one-arm study only 
using data collected from the CPET test conducted at the beginning of the trial.  
General Procedures 
Informed Consent and Baseline Data 
After eligibility was determined and prior to study enrollment, all patients were 
given a complete explanation of the EQUAL phase II trial and were allowed time to look 
over all consent forms.  After the patient was provided with the information and the 
investigator was confident that participation implications were understood, patients were 
asked to sign the approved informed consent form. After the informed consent form was 
signed, patients were scheduled to participate in the initial battery of assessments. All 
patients underwent the exact same testing protocol at baseline and at the completion of 
the EQUAL study phase II protocol which included physical, functional, and 
psychosocial measures. For this study, only data from the CPET test conducted at 
baseline were used.  
For the EQUAL phase II trial, patients were randomized into the intervention or 
to a standard of care group. For the current study, data from all patients during the 
baseline CPET were used regardless of group placement for the EQUAL phase II trial. 
Prior to testing, patients were asked to follow American College of Sports Medicine 
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(ACSM) pre-testing guidelines (ACSM, 2013).  Medical personnel part of the research 
team collected demographic data (age, gender, language preference, disabilities, etc.) and, 
on the day of the initial assessment, resting vital measurements including resting heart 
rate (RHR), BP, temperature and oxygen saturation (SpO2%).  
 
Cardiopulmonary Exercise Test (CPET) 
A cardiopulmonary exercise test (CPET) using standard procedures was used to 
determine VO2 peak. A member of the research team familiarized patients with the cycle 
protocol.  The equipment was adjusted to fit the patient to achieve approximately 120° of 
extension of the lower leg when the pedal was closest to the ground. Patients were also 
fitted for a mask that was used to collect expiratory gases for the VO2 analysis.  
Prior to beginning the cycling protocol, patients sat in a resting state in order to 
collect two minutes of resting metabolic data via expiratory gas analysis while seated on 
the bike.  Patients then cycled for 2 minutes at a resistance of 0 Watts as a warm-up, and 
the test started immediately following the warm-up period.   
The initial workload used was 25 Watts, and workload increments were determined by 
medical history and patient’s metabolic response during the first two minutes of cycling 
during the warm up.  Workload increased 5-20 Watts, depending on the physical state of 
the patient, per minute until patients reached volitional fatigue.  
 Test termination criteria were: volitional fatigue, achievement of a respiratory 
exchange ratio (RER) of greater than 1.10, or limitation by symptoms.  Symptoms that 
ended a test immediately included chest pain, ischemic changes on EKG, arterial oxygen 
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saturation of 85% or less, blood pressure response considered abnormal to exercise 
conditions, dizziness or nausea.  
During the test HR, RPE, BP and VO2 were recorded.  HR values were recorded 
every 10 seconds and RPE was recorded at the end of every minute before increasing to 
the next workload.  The average of the 3 highest values of oxygen uptake during the last 
minute of the test were used to determine VO2 peak. Following the test, patients were 
allowed to rest and cool down by pedaling at low workload of 10 Watts at a cadence of 
their choice until HR returned to under 120bpm.  This protocol has been used previously 
in cancer populations and has been shown to be appropriate for VO2 peak determination 
(Wood et al, 2013).  
 
VO2peak and HR data  
The HR data were collected during the CPET in intervals of 10 seconds. Using 
the peak VO2 obtained during the CPET (the averaging of the 3 highest values during the 
last minute of the test prior to termination), percentages of VO2peak  at 40% (low 
intensity), 60% (moderate intensity), and 75% (high intensity) were calculated. From the 
printout results of the CPET, values corresponding to the percentages of the three 
different intensities (low, moderate, and high) were determined using 30 seconds of raw 
VO2 data and were averaged to determine the percentages at 40, 60 or 75% of VO2peak).  
Then, the corresponding heart rates that were collected at the same 30 second interval 
used for the determination of the percent VO2peak intensity were averaged to determine 
the corresponding HR value.  The HRs determined from the VO2peak percentage test were 
used for comparisons to HRs derived from the HRR and 220-age methods of aerobic 
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intensity determination at the three different exercise intensities. Figure 1.0 is a graphical 
representation of how HRs were determined from VO2peak at different percentages. 
 
Figure 1.0: HR(bpm) vs. VO2(ml/(kg*min)). This example data is from the VO2peak test 
of one bone marrow transplant patient who completed the same testing procedure used in 
this study.  
 
 To obtain two different calculated values for each intensity level, which were 
compared to the HR values obtained from the VO2 test, the Heart Rate Reserve (HRR) 
method ((HRmax–RHR)* %intensity + RHR) and the 220-age HR method ((220-age) * % 
intensity) were used at the same three exercise intensities (40%, 60% and 75%).  The 
calculation for 40% was as follows: 40% of HRR (bpm)= (220-age-RHR)*0.40 + RHR.  
A similar process was completed for the 220-age equation, excluding the use of RHR: 
HR @40% (bpm) = (220-age)*0.40. Thus each participant has three HR values (1 actual 
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(from the VO2peak test), 2 calculated (from the HHR and 220-age methods)) for each of 
the three intensities that were investigated.   
Statistical Analysis 
 This is a retrospective study using data from the CPET conducted as part of the 
EQUAL phase II trial.  
 On average, the NC Cancer Hospital receives 50-60 newly diagnosed acute 
leukemia patients per year.  The EQUAL study aims to enroll 30 patients over 2 years.  
Using G-power analysis program, a sample size of 15 patients has 70% power to detect 
an effect size of 0.60.  This analysis was completed using the parameters of a mean 
difference of 6bpm, and a standard deviation of the difference of 10bpm.   
Descriptive statistics of means and standard deviations were calculated for age, 
height, weight, resting heart rate, and maximum HR achieved during the test (True Max).  
An alpha level was set a priori at .05. All statistical analysis was performed using SPSS 
software version 22.0 for Mac OS (IBM Solutions, Durham, NC).   
The three models of aerobic exercise intensity determination (HR intensity 
derived from the CPET Test, HR intensity derived from the HRR method, and HR 
intensity derived from the 220-age equation) computed at three different exercise 
intensities (40%-Low Intensity, 60%-Moderate Intensity, and 75%-High Intensity) were 
compared using One-Way within subjects ANOVA models. If the ANOVA model turned 
out to be significant, post hoc analyses using the Sidak method were used to identify 
where significant differences in HR between methods occurred.  
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CHAPTER FOUR: RESULTS 
 
 
 The purpose of this study was to compare the heart rate values computed from 
heart rate reserve method and the 220-age equation to heart rates obtained from a 
cardiopulmonary maximal exercise test for the determination of aerobic exercise intensity 
in acute leukemia patients undergoing induction treatment.  Fourteen adult acute 
leukemia patients were tested to compare obtained heart rates from the cardiopulmonary 
maximal test to the calculated heart rates from the heart rate reserve method and 220-age 
equation.  Subject characteristics are presented in Table 1.0.   
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Table 1.0: Subject Characteristics  
Subject Age Weight (kg) Height (cm) Resting Heart Rate (bpm) 
1 34 69.8 155 95 
2 58 90.3 187.9 59 
3 64 86.5 165 98 
4 40 128 198.1 81 
5 57 102.2 184.2 77 
6 43 95.5 182 86 
7 28 116.6 164 93 
8 67 97.7 188 67 
9 67 47.5 153 69 
10 57 74.1 160 57 
11 64 74.1 163 57 
12 69 93 187 89 
13 60 94.8 182.5 60 
14 39 60.6 188 75 
Mean ± SD 53 ± 14 87.9 ± 21.4 175.6 ± 14.8 76 ± 15 
Min – Max 28 – 69 47.5 – 128.0 153.0 – 198.1 57 – 98  
Range 41 80.5 45.1 41 
 
 Descriptive statistics on the results of calculations of HR at % VO2peak test and HR 
calculations using the heart rate reserve (HRR) and 220-age equations at low (40%), 
moderate (60%) and high (75%) intensities are presented in Tables 2.0, 3.0, and 4.0. 
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Table 2.0: Calculated HRs for Low Intensity (40%)  
Subject HRR 
(bpm) 
220-age 
(bpm) 
HR at % VO2peak 
(bpm) 
% True Max 
(bpm) 
1 131 74 147 51 
2 100 65 89 51 
3 121 62 127 62 
4 121 72 120 62 
5 111 65 85 48 
6 122 71 112 68 
7 133 77 114 66 
8 101 61 82 50 
9 103 61 104 49 
10 99 65 68 46 
11 97 62 92 64 
12 114 60 104 41 
13 100 64 68 53 
14 117 72 92 57 
Mean (± SD) 112 (± 12)* 67 (± 6)A 100 (± 23)*A 55 (± 8) 
HRR= Heart Rate Reserve; bpm=Beat per minute; *p≤0.05; A p≤0.05 
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Figure 2.0: Heart Rate(bpm) vs. Age Rank* of Subjects at Low Intensity (40%).
 
*Age rank is by subject for all 14 subjects included in study.  Youngest subject was 
assigned #1, continuing to oldest subject at #14. 
   
At 40% intensity, there was a significant difference between the heart rate reserve 
method and the heart rates derived from the percent of VO2peak test (HRR=112±12, 
HR@VO2=100±22, p=.000). At the low intensity of 40%, the HRR method 
overestimated HR when compared to the HR obtained from using the percent of VO2peak. 
At 40% intensity, there was a significant difference between the 220-age equation and the 
heart rates derived from the percent of VO2peak test (220-age=67±6, HR@VO2=100±22, 
p=.026).  At the low intensity of 40%, the 220-age equation underestimated HR when 
compared to the % VO2peak calculation.   
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Table 3.0: Calculated HRs for Moderate Intensity (60%) 
Subject HRR 
(bpm) 
 
220-age 
(bpm) 
HR at % VO2peak 
(bpm) 
% True Max 
(bpm) 
1 150 112 154 77 
2 121 97 100 77 
3 133 94 144 92 
4 140 108 136 94 
5 129 98 104 72 
6 141 106 126 103 
7 152 115 136 98 
8 119 92 97 74 
9 119 92 111 74 
10 121 98 77 68 
11 116 94 102 96 
12 126 91 110 62 
13 120 96 73 79 
14 139 109 106 85 
Mean (±SD) 130 (± 12)* 100 (± 8) 113 (± 24)* 82 (± 13) 
HRR= Heart Rate Reserve; bpm=Beat per minute; *p≤0.05 
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Figure 3.0: Heart Rate(bpm) vs. Age Rank* of Subjects at Moderate Intensity (60%). 
 
*Age rank is by subject for all 14 subjects included in study.  Youngest subject was 
assigned #1, continuing to oldest subject at #14.   
 
At 60% intensity, there was a significant difference between the HRs obtained 
from the heart rate reserve method and the heart rates derived from the percent of VO2peak 
test (HRR=130±12, HR@VO2=113±24, p=.004). At the moderate intensity of 60%, the 
HRR method overestimated HR when compared to HR obtained from calculating HR 
using the percent VO2peak. 
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Table 4.0: Calculated HRs for High Intensity (75%) 
Subject HRR 220-age HR at % VO2peak % True Max 
1 163 140 156 96 
2 136 122 111 96 
3 142 117 149 116 
4 155 135 146 117 
5 142 122 107 90 
6 154 133 162 128 
7 167 144 150 123 
8 132 115 109 93 
9 132 115 119 92 
10 137 122 89 86 
11 131 117 107 120 
12 136 113 125 77 
13 135 120 83 99 
14 155 136 115 107 
Mean (± SD) 144 (± 12)* 125 (± 10) 123 (± 25)* 103 (± 16) 
HRR= Heart Rate Reserve; bpm=Beat per minute; *p≤0.05 
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Figure 4.0: Heart Rate(bpm) vs. Age Rank* of Subjects at High Intensity (75%). 
 
*Age rank is by subject for all 14 subjects included in study.  Youngest subject was 
assigned #1, continuing to oldest subject at #14.   
 
At 75% intensity, there was a significant difference between the heart rate reserve 
method and the heart rates derived from the percent of VO2peak test (HRR=144±12, 
HR@VO2=124±25, p=.003).  At the high intensity of 75%, the HRR method 
overestimated HR when compared to HR obtained from calculating HR using the percent 
VO2peak.   
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CHAPTER FIVE: DISCUSSION 
 
Overview 
 
 In the acute leukemia population, the prescription of exercise is challenging due 
to not only the intense treatment schedules and side effects, but also the ability of 
hospitals to prescribe exercise based on cardiorespiratory testing.  Not every hospital has 
the equipment and personnel to perform VO2 testing on this patient population, thus 
requiring exercise intensity prescription to vary based on availability of testing methods. 
In previous studies, exercise prescriptions varied significantly. Some researchers used 
RHR+ 30bpm (Chang, 2007), 40-50% of HRR (Battaglini, 2009), and 60-75% of HRR 
(Alibhai, 2012).  For the purpose of practicality in these hospital settings, the Heart Rate 
Reserve method and 220-age equation have been used in this population to prescribe 
exercise intensity without the benefit of a cardiorespiratory maximal exercise test.  
However, if one is looking for prescription with a great level of precision, to date, no 
study has examined the precision of using practical methods of exercise intensity 
determination such as the HRR or the 220-age equation in leukemia patients initiating 
treatment. Therefore, it is not known if using these exercise intensity practical 
quantification methods provide any useful information when used to promote exercise 
training adaptation in this cancer population. Therefore, the purpose of this study was to 
compare the heart rate values calculated from the Heart Rate Reserve and 220-age 
equations and the heart rate values obtained from the VO2peak test for the determination of 
aerobic exercise intensity in acute leukemia patients undergoing induction chemotherapy.  
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The values from each of the three methods were compared at three different intensity 
levels: low (40%), moderate (60%) and high (75%).  This study was unique in its 
comparison of the previously used methods of Heart Rate Reserve and 220-age equations 
to the gold standard method of VO2 tests.  The comparison of all three methods across 
several intensity levels allowed us to examine the accuracy of such calculated methods 
when compared to a gold standard method such as VO2.   
At the low intensity of 40%, the results indicated that both of the methods were 
significantly different from the HRs derived from the VO2peak test and thus neither was an 
acceptable method for determination of aerobic intensity.  After studying the individual 
HRs of the subjects, the wide range of heart rates responses was probably the main reason 
for the non-significant findings observed in the current study. It is also important to note, 
that this was an evaluation of different methods of exercise intensity quantification using 
one single exercise bout performed to maximal effort. Considering that HRs tend to vary 
significantly in this patient population, mostly due to different treatments effects on the 
patients physiology, HRs may not be the most appropriate way to prescribe training 
thresholds in this patient population.  
The HRR overestimation when compared to the HR at %VO2peak may be due to an 
increase in fluids, a decreased hemoglobin capacity or other physiological alterations due 
to the disease and treatment that can affect HRs.  The underestimation by the 220-age 
equation may be due to the resting heart rate not being included in the calculation.  In this 
population the resting heart rates were often above the estimated 220-age value at 40% 
thus leading to underestimation in all participants tested when compared to the HR at 
%VO2.  
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Due to these large differences, another method of exercise intensity determination 
could potentially be used such as a perceived rate of exertion.  The physiological changes 
due to the treatment and its side effects may change the daily ability of this cancer 
population to perform physical work and a subjective measurement to ascertain how they 
feel and how they are able to perform on any given day may assist trainers and help care 
providers to quantify and monitor their exercise intensity until a better method of exercise 
quantification is explored. 
At the moderate level intensity of 60%, there was no significant difference 
between the 220-age equation and the HRs derived from the VO2peak test at 60% intensity 
despite a difference of 13 bpm between methods.  This difference of 13 bpm is clinically 
significant and therefore the results of this study should be interpreted with caution. The 
13 bpm lower HR produced by the 220-age equation is large enough to significantly 
compromise the accuracy of the exercise prescription by under-prescribing an intensity 
that is aimed to promote desirable changes in certain physiological parameters, such as 
cardiorespiratory fitness.  
At the moderate intensity, the cardiorespiratory system is working harder to 
supply the muscles with oxygen more quickly to be able to maintain a higher level of 
force production.  The increased cardiac output required at this intensity may cause the 
heart rates to become more similar to the predicted equations as their intensity level 
increases in order to maintain the higher level of output and compensate for reduced 
oxygen carrying capacity.  The low sample size and nature of the study does not allow for 
this to be verified, but more participants are needed to determine if these inferences are 
potentially the reason for the HR differences.  
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The HRR method again overestimated when compared to the HRs from VO2peak, 
just as it did at the low (40%) intensity.  The reasons for this overestimation are likely the 
same as those for the low intensity – a decreased ability to carry oxygen as a result of the 
disease or the myelosuppression from chemotherapy.  
At the high intensity of 75%, similar results to the moderate intensity were found.  
There was again no significant difference between the 220-age method and the HRs 
derived from the VO2peak test, though at this intensity the difference between the means 
was only 2bpm, which confirms that at higher intensities, there is a diminished 
heterogeneity of HR responses between subjects due to a larger cardiac output needed for 
the subjects to be able to maintain this higher level of power output.  As seen at the other 
intensities, the HRR method overestimated HRs when compared to the HRs derived from 
the HR% of VO2peak.   
Though the statistical outcomes at the moderate and high intensity levels were 
more favorable with the 220-age showing no significant differences, the overall picture 
when looking at individual participants is much different.  Not only is there wide 
variation between the two prediction methods and the HRs from the VO2peak test, but also 
the variation is not systematic or consistent between or even within participants.  These 
erratic differences across intensities suggest that another method or scale might need to 
be included in the determination of exercise intensity in this specific population.  As 
patients go through treatment, their exercise tolerance changes daily due to infections, 
fluids shifts, treatment side effects and the disease process itself.  For practicality and 
scalability purposes without compromising prescription accuracy, a subjective parameter 
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based on the daily physical outlook of the participant might be used as a multiplier or 
scale to better judge intensity without relying solely on heart rate.   
Based on the results of this study, in terms of direct application in a hospital 
setting, neither the HRR method nor the 220-age equation appear to be reliable methods 
for the determination of exercise intensity using HRs due to the high HR variations 
between patients at each level of intensity though statistically there was no difference 
shown using the 220-age equation at moderate and high intensity levels.  The differences 
of 10-12 bpm between the equation and the actual HR from the VO2 are substantial 
especially in this patient population which experiences changes in exercise tolerance 
depending on their cancer and its treatments.  At this time and based on the results of this 
study, it is recommended that for this patient population, heart rate equations and heart 
rate in general should not be used exclusively to determine exercise intensity.  As 
discussed above, including another parameter along with heart rate, or even testing 
another intensity determination method might produce more accurate results than those 
seen in this study.  However, at this time only heart rate and RPE have been used in the 
previous studies to prescribe exercise and this is the first study to look at the accuracy of 
any methods so no positional statement as to the recommended method can be made at 
this time.   
In a new study by Scott in 2014 there was significant HR and VO2peak variability 
between two peak tests performed 5.6±5.5 days apart in early stage prostate cancer 
patients. In terms of HR, the mean difference between tests was not large but the 
variation for some individual participants was as great as 15bpm.  Physiologically heart 
rate can be affected by a variety of factors including fluid levels, stress, medications, and 
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others. Due to the fact that the main objective of exercising ALP during treatment is the 
maintenance of overall physical function, and the attainment of a training response is not 
always possible, for patients experiencing less treatment-related side-effects, a training 
progression aiming to produce more prominent positive response should potentially be 
explored; therefore future studies must be conducted to examine the most appropriate and 
precise way to prescribe the training dose to promote a more specific physiological 
responses. It may be, that for this cancer population, functional training including more of 
a resistance training focus would be more appropriate and the cardiovascular component 
of the overall fitness and health of the subject be maintained with light doses of aerobic 
training where the intensity determination may be done based on each patient’s capacity 
determined on a daily basis.  Therefore, it is paramount that future studies examine 
different training protocols, with different exercise intensities, along with the examination 
of more appropriate ways of quantifying exercise intensity, specially aerobic training, in 
this very unique cancer population of ALP.   
Study Limitations  
 As mentioned prior, the sample size for this study was small. Preliminary analysis 
of the first 9 patients collected indicated HRR as a better prediction method than 220-age 
at all intensity levels.  However, the addition of just the final 5 patients was enough of a 
difference to change the statistical outcomes to favor the 220-age equation at moderate 
and high intensities.  Therefore, a larger sample size appears to be needed so more 
definite conclusions can be made on the prescription of aerobic exercise intensity using 
HR in this cancer population.   
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 Within the acute leukemia participants group for this study, there was variation in 
age, 28 to 69 years old, as well as large differences in resting heart rate values from 57 to 
98 beats per minute.  Some of these heart rate values may also have been different based 
on factors such as medications and starting of treatment prior to completion of the 
VO2peak test.  Out of the 14 patients tested, one was on medication that suppressed their 
heart rate and blood pressure, which affected both the resting and exercise heart rate 
values.  This was due to the levels of stress and anxiety exhibited by the patient prior to 
enrollment and not to a cardiovascular comorbidity.  He was cleared to participate in the 
study and experienced no adverse effects during testing.   
Since this study was developed as a preliminary examination of alterations in HR 
and its influence on training threshold determination using data from a larger trial 
designed to evaluate other outcomes, a future experiment should focus specifically on the 
HRs and potential alterations HR may have during treatment. Nevertheless, the result of 
this study may be used to inform the calculation of power for future trials so the results of 
this preliminary study can be confirmed or refuted. 
 Recommendations for Future Research  
First, this study should be continued or replicated with a larger sample.  It is also 
recommended that this study design should be used in other cancer populations to 
determine appropriate methods for determination of aerobic exercise intensity.  The 
differences in treatment as well as the disease processes may cause their heart rate and 
cardiovascular response to vary from those seen in acute leukemia patients. Therefore it 
is recommended that future studies should evaluate the influence of these factors on HRs 
responses not only in ALP but also in other cancer populations.  
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At this time, heart rate continues to be one of the most practical methods to 
prescribe and track exercise intensity in hospitals and other settings where more precise 
methods used in laboratory research such as prescribing exercise based on the results of 
VO2max testing or from lactate profiling are not available or even feasible. Since HR 
variations are commonly observed not only in cancer patients but also in athletic 
populations, the use of HR in the medical setting should be used more as a monitoring 
method to increase the safety of patients while exercising. Other methods of aerobic 
exercise intensity quantification, such as the creation of methods that encompasses 
physiological and patient rated exercise tolerability feelings may prove in the future to be 
a better option for patients whose physical and functional capacities vary significantly 
day to day.    
Conclusion 
 Based on the results of this study, of the heart rate methods, the 220-age equation 
was not significantly different from the HRs at %VO2peak for the moderate and high 
intensities.  However, the differences between the methods both between and within 
patients at all intensities studied leads to the conclusion that neither the heart rate reserve 
method or 220-age equation should be solely used to determine exercise intensity in this 
population.  The exploration of other parameters and methods to be used alone or in 
conjunction with heart rate to better determine physical exertion during induction 
chemotherapy is recommended.    
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APPENDIX 1.0: EXERCISE PRESCRIPTIONS OF PREVIOUS STUDIES 
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